| 578.54 0.91 (0.16%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 710.01 | 1-year : | 829.29 |
| Resists | First : | 607.89 | Second : | 710.01 |
| Pivot price | 563.66  |
|||
| Supports | First : | 552.08 |
Second : | 517.59 |
| MAs | MA(5) : | 576.87 |
MA(20) : | 554.88 |
| MA(100) : | 502.63 |
MA(250) : | 409.81 |
|
| MACD | MACD : | 17  |
Signal : | 16.8 |
| %K %D | K(14,3) : | 64.6 |
D(3) : | 64.2 |
| RSI | RSI(14): 61.4 |
|||
| 52-week | High : | 607.89 | Low : | 272.11 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ UTHR ] has closed below upper band by 32.3%. Bollinger Bands are 65.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 582.93 - 585.17 | 585.17 - 587.75 |
| Low: | 566.58 - 569.01 | 569.01 - 571.8 |
| Close: | 574.03 - 577.92 | 577.92 - 582.4 |
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Tue, 14 Apr 2026
United Therapeutics CFO Edgemond sells $5.75 million in UTHR stock - Investing.com
Tue, 14 Apr 2026
Rothblatt, United Therapeutics CEO, sells $5.5 million in stock By Investing.com - Investing.com India
Mon, 13 Apr 2026
A Look At United Therapeutics (UTHR) Valuation After RMAT Win And Tyvaso Phase 3 Success - Sahm
Sun, 12 Apr 2026
United Therapeutics stock surges 32% in 6 months: Here's why - MSN
Sat, 11 Apr 2026
United Therapeutics price target raised to $519 from $471 at Morgan Stanley - Yahoo Finance
Fri, 10 Apr 2026
Analyst Ratings Update: United Therapeutics (UTHR) Current Price Target Raised | UTHR Stock News - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 98 (%) |
| Shares Short | 2,840 (K) |
| Shares Short P.Month | 1,840 (K) |
| EPS | 27.87 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 162.6 |
| Profit Margin | 41.9 % |
| Operating Margin | 44.9 % |
| Return on Assets (ttm) | 12.4 % |
| Return on Equity (ttm) | 19.7 % |
| Qtrly Rev. Growth | 7.4 % |
| Gross Profit (p.s.) | 63.88 |
| Sales Per Share | 72.55 |
| EBITDA (p.s.) | 36.5 |
| Qtrly Earnings Growth | 24.5 % |
| Operating Cash Flow | 1,560 (M) |
| Levered Free Cash Flow | 582 (M) |
| PE Ratio | 20.75 |
| PEG Ratio | 0 |
| Price to Book value | 3.55 |
| Price to Sales | 7.97 |
| Price to Cash Flow | 16.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|